16 completed, 6 terminated, 3 unknown. 16 Phase 3, 5 Phase 4, 2 Phase 2, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 12, Terminated 3, Unknown 1 |
| Phase 4 | 5 | Terminated 2, Unknown 2, Completed 1 |
| Phase 2 | 2 | Completed 2 |
| Early Phase 1 | 1 | Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow Quetiapine XR: new trials by email Literature Review of Quetiapine XR trials Research Report on Quetiapine XR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy Seltorexant, Matching placebo to Seltorexant, Quetiapine XR - Depressive Disorder, Major | Phase 3 | Completed | Janssen Research & Development, LLC | 757 | 2020-09-15 | 2025-08-13 |
| A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. SEP363856, quetiapine XR - Schizophrenia | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 305 | 2019-11-21 | 2025-12-31 |
| A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR - Depressive Disorder, Major | Phase 2 | Completed | Janssen Research & Development, LLC | 107 | 2017-12-12 | 2025-04-29 |
| The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope SSRI monotherapy, Seroquel XR adjunctive - Major Depressive Disorder | Phase 4 | Unknown | Inje University | 60 | 2011-05-01 | 2012-11-01 |
| The Quietude Study: Quetiapine Use for Agitated Depression Quetiapine XR, Escitalopram - Depression With Prominent Agitation | Phase 3 | Terminated | Physicians Research And Education Network | 250 | 2010-10-01 | 2014-01-08 |
| Efficacy of Quetiapine XR Versus Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder Quetiapine, Placebo - Bipolar Disorder | Phase 3 | Completed | Centro de Investigación Biomédica en Red de Salud Mental | 28 | 2010-09-01 | 2012-09-19 |
| Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder Quetiapine XR, Placebo - Bipolar Disorder, Cognitive Impairment | Phase 4 | Terminated | Emory University | 32 | 2010-01-01 | 2014-04-17 |
| Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Quetiapine XR - Schizophrenia, Psychosis | Phase 4 | Unknown | Bayside Health | 72 | 2009-10-01 | 2009-09-29 |
| Quetiapine XR in Schizophrenic Patients Quetiapine XR - Schizophrenia | Phase 3 | Terminated | Hannover Medical School | 5 | 2009-09-01 | 2011-11-11 |
| Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat seroquel xr, CBT - Major Depressive Disorder, Generalized Anxiety Disorder | Not applicable | Completed | Icahn School of Medicine at Mount Sinai | 62 | 2009-09-01 | 2018-02-15 |
| Quetiapine in Specific Phobia Quetiapine XR, Placebo - Specific Phobia | Phase 2 | Completed | University Hospital Muenster | 60 | 2009-04-01 | 2011-03-31 |
| Pediatric Bipolar Depression Quetiapine XR, Placebo - Bipolar Depression | Phase 3 | Completed | AstraZeneca | 193 | 2009-01-01 | 2014-07-15 |
| Clinical Benefits of Seroquel XR in Anxiety Disorder Quetiapine XR - Schizophrenia, Anxiety | Phase 3 | Unknown | Corporation de Recherche en Neuropsycho Pharmacologie de Quebec | 40 | 2008-12-01 | 2012-08-27 |
| Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia Lurasidone HC1, Quetiapine XR - Chronic Schizophrenia | Phase 3 | Completed | Sumitomo Pharma America, Inc. | 240 | 2008-12-01 | 2015-06-12 |
| Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients Quetiapine XR, Lithium carbonate, SSRI/Venlafaxine - Major Depressive Disorder, Treatment Resistant Depression | Phase 3 | Completed | AstraZeneca | 688 | 2008-11-01 | 2012-05-23 |
| Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia. Lurasidone, Quetiapine XR, Placebo - Schizophrenia | Phase 3 | Completed | Sumitomo Pharma America, Inc. | 488 | 2008-10-01 | 2016-03-17 |
| Schizophrenic Patients in Integrated Care Quetiapine XR, Integrated Care Program (ICP) - Schizophrenia, Schizoaffective Disorder | Phase 4 | Terminated | AstraZeneca | 7 | 2008-07-01 | 2012-07-30 |
| Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder Quetiapine XR, Placebo - Major Depressive Disorder, Generalized Anxiety Disorder | Phase 3 | Terminated | Keming Gao | 23 | 2008-06-01 | 2016-12-29 |
| Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD) Quetiapine XR, Placebo for quetiapine XR - Bipolar Disorder, Anxiety | Phase 3 | Completed | University Hospitals Cleveland Medical Center | 120 | 2008-04-01 | 2016-12-29 |
| A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients quetiapine XR, placebo - Panic Disorder | Phase 4 | Completed | Indiana University | 26 | 2008-02-01 | 2016-01-21 |
Showing 20 of 25. Sign in to see all of them.
Schizophrenia (8) · Depressive Disorder, Major (6) · Anxiety Disorders (4) · Bipolar Disorder (4) · Depression (3) · Generalized Anxiety Disorder (3) · Psychotic Disorders (2) · Aggression (1) · Alcoholism (1) · Cognitive Dysfunction (1) · Depressive Disorder (1) · Depressive Disorder, Treatment-Resistant (1) · Panic Disorder (1) · Phobia, Social (1) · Phobia, Specific (1)
AstraZeneca (5) · Janssen Research & Development, LLC (2) · Sumitomo Pharma America, Inc. (2) · Bayside Health (1) · Centro de Investigación Biomédica en Red de Salud Mental (1) · Corporation de Recherche en Neuropsycho Pharmacologie de Quebec (1) · Duke University (1) · Emory University (1) · Hannover Medical School (1) · Icahn School of Medicine at Mount Sinai (1) · Indiana University (1) · Inje University (1) · Keming Gao (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Physicians Research And Education Network (1)
United States (14) · Russia (6) · Germany (5) · Romania (5) · Ukraine (5) · Canada (4) · Belgium (3) · Bulgaria (3) · India (3) · Spain (3) · Australia (2) · Colombia (2) · Italy (2) · Mexico (2) · Poland (2)
Allan Young, MD (1) · Ana Gonzalez Pinto (1) · Andrew W. Goddard, M.D. (1) · Belen Arranz (1) · Benedikt Amann (1) · Birgit Ekholm, PhD (1) · Celso Arango (1) · Eduard Vieta, PhD (1) · Gabriel Selva (1) · Jack Hirschowitz, MD (1) · Jayashri Kulkarni, Prof (1) · Jeffrey J Rakofsky, MD (1) · Jeronimo Saiz (1)
PMID 24035633, PMID 26117157, PMID 23070803, PMID 23415311, PMID 23583011, PMID 23810357, PMID 23953270, PMID 24330860, PMID 24955752, PMID 25007003, PMID 26379759, PMID 34751928, PMID 39144777, PMID 41795948
2019 (1)